Your browser is no longer supported. Please, upgrade your browser.
OASM Oasmia Pharmaceutical AB (publ) monthly Stock Chart
OASM [NASD]
Oasmia Pharmaceutical AB (publ)
Index- P/E- EPS (ttm)-0.29 Insider Own- Shs Outstand83.03M Perf Week-6.29%
Market Cap123.72M Forward P/E- EPS next Y- Insider Trans- Shs Float53.45M Perf Month-25.50%
Income- PEG- EPS next Q- Inst Own0.14% Short Float0.12% Perf Quarter-25.89%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.26 Perf Half Y-39.65%
Book/sh0.61 P/B2.45 EPS next Y- ROA- Target Price6.00 Perf Year-17.68%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.94 - 5.70 Perf YTD-50.74%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-73.86% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low58.83% ATR0.18
Employees60 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)44.72 Volatility9.05% 8.91%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.02 Prev Close1.56
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume248.46K Price1.49
Recom2.00 SMA20-13.88% SMA50-10.80% SMA200-43.07% Volume3,934 Change-4.49%
Sep-12-16Initiated Rodman & Renshaw Buy $6
Aug-16-19 03:00PM  Oasmia Pharmaceutical AB (OASM), Eagle Bancorp, Inc. (EGBN) & 3M Company (MMM)  Class Action Update - Bronstein, Gewirtz & Grossman, LLC GlobeNewswire
02:35PM  Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Against Oasmia Pharmaceutical AB OASM GlobeNewswire
10:05AM  Oasmia Pharmaceutical AB (OASM), Eagle Bancorp, Inc. (EGBN) & 3M Company (MMM) - Class Action - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
09:25AM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Oasmia Pharmaceutical AB To Contact The Firm ACCESSWIRE
Aug-15-19 10:30AM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Oasmia Pharmaceutical AB To Contact The Firm Newsfile +8.33%
Aug-14-19 10:00AM  Oasmia Pharmaceutical AB (OASM), Eagle Bancorp, Inc. (EGBN) & 3M Company (MMM) - Class Action Update - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE -10.00%
Aug-13-19 09:20PM  IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Oasmia Pharmaceutical AB and Encourages Investors with Losses to Contact the Firm ACCESSWIRE -7.51%
03:00PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Oasmia Pharmaceutical AB To Contact The Firm ACCESSWIRE
09:25AM  INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Oasmia Pharmaceutical AB and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Aug-12-19 06:30PM  IMPORTANT INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Oasmia Pharmaceutical AB and Encourages Investors with Losses to Contact the Firm ACCESSWIRE +8.81%
02:16PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Oasmia Pharmaceutical AB To Contact The Firm GlobeNewswire
09:54AM  Oasmia Pharmaceutical AB (OASM), Eagle Bancorp, Inc. (EGBN) & 3M Company (MMM) - Class Action Reminder - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Aug-11-19 07:17PM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against L Brands, National General, Mallinckrodt, and Oasmia and Encourages Investors to Contact the Firm GlobeNewswire
Aug-09-19 08:00PM  ROSEN, A TOP RANKED LAW FIRM, Reminds Oasmia Pharmaceutical AB Investors of Important Deadline in Securities Class Action First Filed by the Firm; Encourages Investors with Losses in Excess of $100K to Contact the Firm OASM GlobeNewswire
03:00PM  SHAREHOLDER ALERT - Oasmia Pharmaceutical AB (OASM) - Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action and Lead Plaintiff Deadline: September 27, 2019 GlobeNewswire
10:09AM  SHAREHOLDER ALERT - Oasmia Pharmaceutical AB (OASM) - Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action and Lead Plaintiff Deadline: September 27, 2019 ACCESSWIRE
Aug-07-19 08:13PM  CLASS ACTION REMINDER: Hagens Berman Reminds Investors in Oasmia Pharmaceutical AB (OASM) of September 27, 2019 Lead Plaintiff Deadline GlobeNewswire
05:00PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Oasmia Pharmaceutical AB To Contact The Firm ACCESSWIRE
10:08AM  SHAREHOLDER ALERT - Oasmia Pharmaceutical AB (OASM) - Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action and Lead Plaintiff Deadline: September 27, 2019 ACCESSWIRE
Aug-06-19 07:16PM  Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Oasmia Pharmaceutical AB Investors Business Wire
04:48PM  Zhang Investor Law Announces Securities Class Action Lawsuit Against Oasmia Pharmaceutical AB OASM GlobeNewswire
03:28PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Oasmia Pharmaceutical AB To Contact The Firm GlobeNewswire
Aug-05-19 09:30PM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Mallinckrodt, Oasmia Pharmaceutical, 3M Company, and Aclaris Therapeutics and Encourages Investors to Contact the Firm GlobeNewswire -7.69%
06:55PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Oasmia Pharmaceutical AB - OASM ACCESSWIRE
06:48PM  Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Oasmia Pharmaceutical AB Business Wire
03:05PM  INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Oasmia Pharmaceutical AB and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
10:07AM  SHAREHOLDER ALERT - Oasmia Pharmaceutical AB (OASM) - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action and Lead Plaintiff Deadline: September 27, 2019 ACCESSWIRE
Aug-02-19 08:40PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Oasmia Pharmaceutical AB To Contact The Firm ACCESSWIRE +5.15%
08:25PM  SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Oasmia Pharmaceutical AB and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
07:09PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Oasmia Pharmaceutical AB - OASM GlobeNewswire
05:30PM  ROSEN, A HIGHLY RANKED LAW FIRM, Reminds Oasmia Pharmaceutical AB Investors of Important Deadline in Securities Class Action Commenced by the Firm; Encourages Investors with Losses in Excess of $100K to Contact the Firm OASM Business Wire
03:00PM  SHAREHOLDER ALERT - Oasmia Pharmaceutical AB (OASM) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Plaintiff Deadline: September 27, 2019 GlobeNewswire
02:03PM  Shareholder Alert: Robbins Arroyo LLP Announces Oasmia Pharmaceutical AB (OASM) Sued for Misleading Shareholders Business Wire
10:58AM  SHAREHOLDER ALERT - Oasmia Pharmaceutical AB (OASM) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Plaintiff Deadline: September 27, 2019 ACCESSWIRE
Aug-01-19 05:57PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Oasmia Pharmaceutical AB To Contact The Firm GlobeNewswire -11.46%
10:00AM  SHAREHOLDER ALERT - Oasmia Pharmaceutical AB (OASM) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Plaintiff Deadline: September 27, 2019 PR Newswire
Jul-31-19 07:10PM  INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Oasmia Pharmaceutical AB and Encourages Investors with Losses to Contact the Firm ACCESSWIRE +8.47%
06:30PM  Rosen, a Leading Law Firm, Files First Securities Class Action Lawsuit Against Oasmia Pharmaceutical AB; Encourages Investors with Losses in Excess of $100K to Contact the Firm OASM GlobeNewswire
04:09PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Oasmia Pharmaceutical AB To Contact The Firm PR Newswire
09:44AM  IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Oasmia Pharmaceutical AB and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Jul-30-19 06:00PM  Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Oasmia Pharmaceutical AB Investors Business Wire -8.27%
04:55PM  SHAREHOLDER DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Oasmia Pharmaceutical AB and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
03:26PM  INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Oasmia Pharmaceutical AB Investors (OASM) Business Wire
12:27PM  ROSEN, A TOP RANKED LAW FIRM, Files First Securities Class Action Lawsuit Against Oasmia Pharmaceutical AB; Encourages Investors with Losses in Excess of $100K to Contact the Firm OASM Business Wire
11:52AM  IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Oasmia Pharmaceutical AB and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
10:57AM  SHAREHOLDER ALERT - Oasmia Pharmaceutical AB (OASM) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Plaintiff Deadline: September 27, 2019 ACCESSWIRE
Jul-29-19 09:30PM  Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Oasmia Pharmaceutical AB (NASDAQ: OASM) and Encourages Oasmia Investors to Contact the Firm GlobeNewswire +10.34%
08:11PM  OASM CLASS ACTION ALERT: Hagens Berman Alerts Investors in Oasmia Pharmaceutical AB (OASM) to Securities Fraud Class Action GlobeNewswire
03:43PM  EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Oasmia Pharmaceutical AB - OASM PR Newswire
Jul-26-19 05:06PM  Lifshitz & Miller LLP Announces Investigation of Caesars Entertainment Corporation, Del Frisco's Restaurant Group, Inc., Diebold Nixdorf, Inc., FedEx Corporation, Oasmia Pharmaceuticals, Shore Community Bancorp, Verb Technology Company and WageWorks, Inc. PR Newswire
Jul-24-19 09:55AM  ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Oasmia Pharmaceutical AB and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Jul-19-19 04:30PM  ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Oasmia Pharmaceutical AB and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
10:55AM  EQUITY ALERT: Rosen Law Firm Continues to Investigate Securities Claims Against Oasmia Pharmaceutical AB - OASM GlobeNewswire
Jul-18-19 11:26AM  INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Oasmia Pharmaceutical AB and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
Jul-17-19 06:00PM  Glancy Prongay & Murray LLP Continues Investigation on Behalf of Oasmia Pharmaceutical AB Investors (OASM) Business Wire -11.61%
03:40PM  SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Oasmia Pharmaceutical AB and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
02:59PM  INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Oasmia Pharmaceutical AB Investors (OASM) Business Wire
Jul-16-19 04:53PM  INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Oasmia Pharmaceutical AB and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
11:10AM  ROSEN, A TOP RANKED LAW FIRM, Continues to Investigate Securities Claims Against Oasmia Pharmaceutical AB - OASM Business Wire
Jul-11-19 09:30PM  Bragar Eagel & Squire, P.C. is Investigating Oasmia Pharmaceutical AB (NASDAQ: OASM) on Behalf of Stockholders and Encourages Investors to Contact the Firm GlobeNewswire -20.80%
08:00PM  Glancy Prongay & Murray LLP Announces Investigation on Behalf of Oasmia Pharmaceutical AB Investors (OASM) Business Wire
04:59PM  INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Oasmia Pharmaceutical AB Investors (OASM) Business Wire
01:46PM  OASMIA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Oasmia Pharmaceutical AB To Contact The Firm GlobeNewswire
10:53AM  Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Oasmia Pharmaceutical AB (OASM) ACCESSWIRE
Jul-10-19 06:22PM  EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Oasmia Pharmaceutical AB - OASM Business Wire -13.08%
05:03PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Oasmia Pharmaceutical AB - OASM GlobeNewswire
Jul-08-19 01:50PM  A Look At Benzinga Pro's Most-Searched Tickers For July 8, 2019 Benzinga +13.43%
09:22AM  Company News for Jul 8, 2019 Zacks
Jun-28-19 02:46PM  OASMIA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Oasmia Pharmaceutical AB To Contact The Firm PR Newswire -23.81%
Jun-08-18 02:30AM  Oasmia Pharmaceutical AB (publ) Year-end report for the financial year May 1, 2017 April 30, 2018 GlobeNewswire +7.18%
Jun-05-18 02:30AM  Results from Oasmia Pharmaceuticals phase III study have been presented at ASCO annual meeting GlobeNewswire
May-30-18 11:45AM  Nexttobe Extends Loan to Oasmia Pharmaceutical GlobeNewswire -8.50%
May-21-18 02:30AM  Oasmia Pharmaceutical Completes Spin-off of Veterinary Oncology Assets to Wholly Owned US Subsidiary, AdvaVet, Inc. GlobeNewswire -7.65%
May-17-18 02:30AM  Results from Oasmia Pharmaceuticals phase III study will be presented at ASCO annual meeting in June GlobeNewswire +6.52%
May-16-18 12:00PM  Notification from Oasmia Pharmaceutical GlobeNewswire
May-08-18 02:30AM  Notification from Oasmia Pharmaceutical AB GlobeNewswire -6.51%
May-02-18 02:45AM  Notification from Oasmia Pharmaceutical AB GlobeNewswire
Apr-24-18 02:00AM  Notification from Oasmia Pharmaceutical AB GlobeNewswire -12.09%
Apr-19-18 02:45AM  Oasmia has completed a private placement of new convertible instruments in a total amount of SEK 26,000,000 GlobeNewswire
Mar-02-18 02:30AM  Oasmia Pharmaceutical AB (publ) GlobeNewswire -6.75%
Feb-19-18 02:30AM  Oasmia Pharmaceuticals Docecal program achieves significant development milestone GlobeNewswire
Dec-06-17 09:25AM  Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q2, 2018 By the Numbers : December 6, 2017 Capital Cube
Sep-18-17 02:02PM  Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q1, 2018 By the Numbers : September 18, 2017 Capital Cube
Aug-08-17 07:00AM  Oasmia Pharmaceutical receives market approval for its Anti-Cancer Drug Doxophos® in Russia GlobeNewswire +13.00%
Jul-12-17 10:54AM  Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q4, 2017 By the Numbers : July 12, 2017 Capital Cube +5.87%
Jun-14-17 07:00AM  Oasmia Pharmaceutical enters into new exclusive marketing and distribution agreement concerning Russia and other CIS markets GlobeNewswire
Mar-22-17 09:28AM  Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q3, 2017 By the Numbers : March 22, 2017 Capital Cube
09:28AM  Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q3, 2017 By the Numbers : March 22, 2017
Jan-23-17 07:00AM  Oasmia Pharmaceutical Announces Strategic Move to Bolster Efforts for its Veterinary Division GlobeNewswire
Jan-19-17 11:53AM  Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q2, 2017 By the Numbers : January 19, 2017 Capital Cube
11:53AM  Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q2, 2017 By the Numbers : January 19, 2017
Dec-21-16 07:00AM  Oasmia Pharmaceutical Reports Positive Results from Study on Weekly Administration of Apealea® (Paclical®) GlobeNewswire
Dec-07-16 09:30AM  Oasmia Pharmaceutical ABs Warrant Programs Fully Subscribed GlobeNewswire
Dec-06-16 10:01AM  Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q2, 2017 By the Numbers : December 6, 2016 Capital Cube
10:01AM  Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q2, 2017 By the Numbers : December 6, 2016
Dec-02-16 10:05AM  Interim report for the period May - October 2016 GlobeNewswire
Nov-22-16 07:49AM  Communiqué from Extraordinary General Meeting 2016 GlobeNewswire
Nov-02-16 07:24AM  Nexttobe Extends Loan to Oasmia Pharmaceutical GlobeNewswire
Oct-31-16 02:32PM  Oasmia Buys Estrogen Receptor Cancer Drug (OASM) at Investopedia
07:25AM  Change in number of shares and voting rights in Oasmia Pharmaceutical AB (publ) GlobeNewswire
Oasmia Pharmaceutical AB develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations based on cytostatics. The company's approved products include Paclical/Apealea for the treatment of ovarian and metastatic breast cancer; and Doxophos for the treatment of various doxorubicin indications. It also develops Docecal for breast cancer; OAS-19 and KB9520 for various cancers; Paccal Vet for mammary carcinoma and squamous cell carcinoma; and Doxophos Vet for lymphoma. Oasmia Pharmaceutical AB was founded in 1988 and is based in Uppsala, Sweden.